Baidu
map

内分泌科

订阅

MedSci主页 / 所有栏目 / 内分泌科

JCEM：长期持续性轻度亚临床甲减可能会增加儿童心血管风险

2014-06-12 MedSci MedSci原创

甲减亚临床心血管
关注

亚临床甲减的心血管风险已得到公认。然而在儿童与青少年中尚不清楚。最新一项研究表明，作者选择了轻度亚临床甲减儿童和青少年（血清TSH浓度在4.5-10 mU/L）水平，但未经任何治疗进行长期随访观察，平均随访3.2±0.4 年。总共选择49例8.5±0.5岁的轻度亚临床甲减儿童，以及49例正常对照儿童。观察收缩压，舒张压，BMI，腰围身高比（WHtR ），脂质水平，同型半胱氨酸水

亚临床甲减的心血管风险已得到公认。然而在儿童与青少年中尚不清楚。最新一项研究表明，作者选择了轻度亚临床甲减儿童和青少年（血清TSH浓度在4.5-10 mU/L）水平，但未经任何治疗进行长期随访观察，平均随访3.2±0.4 年。总共选择49例8.5±0.5岁的轻度亚临床甲减儿童，以及49例正常对照儿童。观察收缩压，舒张压，BMI，腰围身高比（WHtR ），脂质水平，同型半胱氨酸水平，血清高敏CRP， fibrinogen, adiponectin, insulin 和HOMA index。结果发现，与正常对照组相比，WHtR (p<0.0001), atherogenic index (p =0.001), triglycerides/HDL-Cholesterol ratio (p= 0.01) 和 homocysteine levels (p=0.002) 都显著上升，而HDL-Cholesterol显著下降 (p=0.003) 。多元回归分析发现BMI是甲状腺状态的独立风险因素，即便校正BMI后，这些变量仍然与TSH水平或亚临床甲减相关。虽然，在儿童中无法征测出心血管风险，但这些指标提示这些儿童将来动脉粥样硬化的可能性更大。


原始出处：
Manuela C, Capalbo D, Wasniewska M, Mattace Raso G, Alfano S, Meli R, De Luca F, Salerno M.CARDIOVASCULAR RISK FACTORS IN CHILDREN WITH LONG-STANDING UNTREATED IDIOPATHIC SUBCLINICAL HYPOTHYROIDISM. J Clin Endocrinol Metab. 2014 May 19:jc20141761.

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2062857, encodeId=99df206285e78, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Fri Oct 24 10:23:00 CST 2014, time=2014-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777476, encodeId=f4ba1e774762a, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Sun Feb 01 03:23:00 CST 2015, time=2015-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082351, encodeId=2ad1208235108, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Wed Jul 30 00:23:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922521, encodeId=580a192252151, content=<a href='/topic/show?id=3f3156324ff' target=_blank style='color:#2F92EE;'>#持续性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56324, encryptionId=3f3156324ff, topicName=持续性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Tue Nov 25 20:23:00 CST 2014, time=2014-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341297, encodeId=064a134129e6b, content=<a href='/topic/show?id=0cb769e593b' target=_blank style='color:#2F92EE;'>#甲减#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69759, encryptionId=0cb769e593b, topicName=甲减)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Sat Jun 14 00:23:00 CST 2014, time=2014-06-14, status=1, ipAttribution=)]
    2014-10-24 achengzhao

    #JCE#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2062857, encodeId=99df206285e78, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Fri Oct 24 10:23:00 CST 2014, time=2014-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777476, encodeId=f4ba1e774762a, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Sun Feb 01 03:23:00 CST 2015, time=2015-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082351, encodeId=2ad1208235108, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Wed Jul 30 00:23:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922521, encodeId=580a192252151, content=<a href='/topic/show?id=3f3156324ff' target=_blank style='color:#2F92EE;'>#持续性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56324, encryptionId=3f3156324ff, topicName=持续性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Tue Nov 25 20:23:00 CST 2014, time=2014-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341297, encodeId=064a134129e6b, content=<a href='/topic/show?id=0cb769e593b' target=_blank style='color:#2F92EE;'>#甲减#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69759, encryptionId=0cb769e593b, topicName=甲减)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Sat Jun 14 00:23:00 CST 2014, time=2014-06-14, status=1, ipAttribution=)]
    2015-02-01 smallant2015

    #JCEM#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2062857, encodeId=99df206285e78, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Fri Oct 24 10:23:00 CST 2014, time=2014-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777476, encodeId=f4ba1e774762a, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Sun Feb 01 03:23:00 CST 2015, time=2015-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082351, encodeId=2ad1208235108, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Wed Jul 30 00:23:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922521, encodeId=580a192252151, content=<a href='/topic/show?id=3f3156324ff' target=_blank style='color:#2F92EE;'>#持续性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56324, encryptionId=3f3156324ff, topicName=持续性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Tue Nov 25 20:23:00 CST 2014, time=2014-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341297, encodeId=064a134129e6b, content=<a href='/topic/show?id=0cb769e593b' target=_blank style='color:#2F92EE;'>#甲减#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69759, encryptionId=0cb769e593b, topicName=甲减)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Sat Jun 14 00:23:00 CST 2014, time=2014-06-14, status=1, ipAttribution=)]
    2014-07-30 ms5353107019656438

    #血管风险#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2062857, encodeId=99df206285e78, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Fri Oct 24 10:23:00 CST 2014, time=2014-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777476, encodeId=f4ba1e774762a, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Sun Feb 01 03:23:00 CST 2015, time=2015-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082351, encodeId=2ad1208235108, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Wed Jul 30 00:23:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922521, encodeId=580a192252151, content=<a href='/topic/show?id=3f3156324ff' target=_blank style='color:#2F92EE;'>#持续性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56324, encryptionId=3f3156324ff, topicName=持续性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Tue Nov 25 20:23:00 CST 2014, time=2014-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341297, encodeId=064a134129e6b, content=<a href='/topic/show?id=0cb769e593b' target=_blank style='color:#2F92EE;'>#甲减#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69759, encryptionId=0cb769e593b, topicName=甲减)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Sat Jun 14 00:23:00 CST 2014, time=2014-06-14, status=1, ipAttribution=)]
    2014-11-25 liuyg0228

    #持续性#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2062857, encodeId=99df206285e78, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Fri Oct 24 10:23:00 CST 2014, time=2014-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777476, encodeId=f4ba1e774762a, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Sun Feb 01 03:23:00 CST 2015, time=2015-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082351, encodeId=2ad1208235108, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Wed Jul 30 00:23:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922521, encodeId=580a192252151, content=<a href='/topic/show?id=3f3156324ff' target=_blank style='color:#2F92EE;'>#持续性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56324, encryptionId=3f3156324ff, topicName=持续性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Tue Nov 25 20:23:00 CST 2014, time=2014-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341297, encodeId=064a134129e6b, content=<a href='/topic/show?id=0cb769e593b' target=_blank style='color:#2F92EE;'>#甲减#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69759, encryptionId=0cb769e593b, topicName=甲减)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Sat Jun 14 00:23:00 CST 2014, time=2014-06-14, status=1, ipAttribution=)]
    2014-06-14 12498cf9m35(暂无昵称)

    #甲减#

    0

相关资讯

ARD：关节炎合并甲减使女性心血管风险增3倍

3月14日，《风湿病年鉴》（Annals of The Rheumatic Diseases）杂志上的一项研究表明，合并甲状腺功能减退症和炎性关节炎的女性罹患心血管疾病(CVD)的风险是对照者的近4倍。 长期以来人们推测甲状腺功能减退症与炎性关节炎可能存在关联，但证据不足。为考察这两种疾病的关联性及其对CVD风险的影响，阿姆斯特丹自由大学医学中心风湿科的Hennie G. Raterman博

妊娠期甲状腺功能异常评估异于普通人群

妊娠期甲状腺疾病的诊断是最让临床医生纠结的临床问题，在2013年中国医师协会内分泌代谢科医师分会年会（2013.7.4-7.6，吉林长春）上，中国医科大学附属第一医院单忠艳教授结合《中国妊娠和产后甲状腺疾病诊治指南》阐述了妊娠合并甲状腺功能异常的管理，以期能为内分泌医生以及产科医生答疑解惑。 单教授指出，鉴于妊娠期的特殊甲状腺生理变化，不能采用普通人群的正常参考范围来进行评估。在评估甲状腺功能的

Stroke：亚临床甲亢为卒中后功能转归不佳危险因素

德国学者的一项研究表明，亚临床甲状腺功能亢进（简称亚临床甲亢）为缺血性卒中后功能转归不佳的危险因素。论文于2013年3月12日在线发表于《卒中》（Stroke）。　　此项前瞻性观察研究共纳入165例缺血性卒中患者。在发病3天内于清晨采集血液样本。依据促甲状腺素水平将患者分别为亚临床甲亢（0.1<促甲状腺素≤0.44 μU/mL）、亚临床甲减（2.5≤促甲状腺素<20 μU/mL）和甲状

医生怕体检？医护群体成癌症高发人群

“一年一度职工健康体检，头夜，忽然有种读书那些年考试前夜的感觉。迈进体检中心，就像当年走进考场的忐忑。那时怕挂了，现在更怕挂了……”2月9日上午，四川大学华西医院耳鼻喉头颈外科主任医师赵宇（微博@罩得住他爸 ）发出这条微博，并很快引起北京协和医院变态反应科主任尹佳（@协和尹佳）的转发评论——“很多医生怕体检”。随后微博继续发酵，诸多医护圈博友纷纷回应： @珊宝的爸爸：你娃运气好，

Stroke：亚临床甲亢为卒中后功能转归不佳危险因素

　　德国学者的一项研究表明，亚临床甲状腺功能亢进（简称亚临床甲亢）为缺血性卒中后功能转归不佳的危险因素。论文于2013年3月12日在线发表于《卒中》（Stroke）。 　　此项前瞻性观察研究共纳入165例缺血性卒中患者。在发病3天内于清晨采集血液样本。依据促甲状腺素水平将患者分别为亚临床甲亢（0.1<促甲状腺素≤0.44 μU/mL）、亚临床甲减（2.5≤促甲状腺素<20&

ATA 2013：甲减治疗未必带来体重减轻

众所周知，世界著名球星“外星人”罗纳尔多是因为甲状腺功能减退导致肥胖而退役的。经过治疗以后，罗纳尔多能不能减肥成功呢？据媒体报道，罗纳尔多日前在马德里出席公关活动，减肥反弹，横肉一脸。　　甲状腺功能减退，通常伴有体重增加。但最近有一项研究发现，与一般人所认为的相反，左旋甲状腺素（LT4）有效治疗虽然能使甲状腺激素水平恢复正常，但在许多患者中却并不伴有体重显著减轻。2013年10月16-20

Baidu
map
Baidu
map
Baidu
map